Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company based in Palo Alto, California, has announced the pricing of its initial public offering. The company priced 7,500,000 Class A ordinary shares at US$10.00 per share, generating total gross proceeds of US$75 million before underwriting discounts and estimated expenses. The shares are scheduled to begin trading on the Nasdaq Capital Market under the ticker symbol FLSC on October 14, 2026.
Offering Structure and Timeline
The offering is expected to close on October 15, 2026, subject to customary closing conditions. Each Class A ordinary share was priced at US$10.00, and the company expects to list on the Nasdaq Capital Market under the ticker FLSC. Jefferies is acting as the sole book-running manager for the transaction, and the registration statement was declared effective by the Securities and Exchange Commission on October 13, 2026.
Capital Structure and Trading
The initial public offering consists solely of Class A ordinary shares, with no warrants or units described in the announcement. Proceeds from the offering will be placed into a trust account pending the completion of an initial business combination. The listing on the Nasdaq Capital Market is expected to provide liquidity and access to public market investors.
Company Purpose and Market Focus
Frazier Life Sciences Acquisition Corp. II was formed to complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. While the company may pursue opportunities in any sector or region, it intends to focus on the biotechnology industry. The leadership aims to identify promising companies that can develop important new therapies for patients while creating value for shareholders.
Leadership and Sponsor Background
The company is sponsored by Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P. Its leadership team includes Chief Executive Officer Albert Cha, M.D., Ph.D., Chairman of the Board of Directors Ben Palleiko, and Chief Business Officer Kevin Li, M.D. The sponsor and management team bring experience in life sciences investing and company building to the search for a business combination.
Prospectus and Regulatory Details
Copies of the prospectus may be obtained from Jefferies LLC at its New York office or by emailing the equity syndicate prospectus department. The document is also available on the Securities and Exchange Commission website at www.sec.gov. The registration statement relating to these securities was declared effective on October 13, 2026.
Forward-Looking Statements
The company cautioned that the press release contains forward-looking statements regarding the expected closing of the offering and the search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all, or that the proceeds will be used as indicated. These statements are subject to risks and uncertainties detailed in the registration statement filed with the SEC.
Overall, the pricing of this US$75 million initial public offering marks a notable step for Frazier Life Sciences Acquisition Corp. II in securing capital for a future business combination. With a focus on the biotechnology sector and an experienced leadership team, the company aims to identify and support an innovative healthcare company. Investors and market participants will watch for the closing of the offering and the subsequent search for a merger target.